David A. Siegel Janux Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 83,000 shares of JANX stock, worth $3.48 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
83,000
Previous 23,600
251.69%
Holding current value
$3.48 Million
Previous $253,000
1134.78%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
123Shares Held
25.3MCall Options Held
92KPut Options Held
161K-
Orbimed Advisors LLC San Diego, CA4.28MShares$179 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$122 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$116 Million0.2% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.35MShares$98.5 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$82.3 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.75B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...